Empiric antibiotic therapy for suspected ventilator-associated pneumonia: A systematic review and meta-analysis of randomized trials

Critical Care Medicine

Volumn 36, Issue 1, 2008, Pages 108-117

  Aarts, Mary Anne W ^a,b   Hancock, Jennifer N ^c   Heyland, Daren ^c   McLeod, Robin S ^a,b   Marshall, John C ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Antibiotics; Critical care; Cross infection; Empirical therapy; Meta analysis; Randomized control trial; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZLOCILLIN; AZTREONAM; CARBENICILLIN; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; GENTAMICIN; IMIPENEM; ISEPAMICIN; LATAMOXEF; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; NETILMICIN; PEFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DATA EXTRACTION; EMBASE; FOLLOW UP; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 37549047587     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000297956.27474.9D     Document Type: Article

References (92)

1. Bergmans DC, Bonten MJ, Gaillard CA, et al: Indications for antibiotic use in ICU patients: A one-year prospective surveillance. J Antimicrob Chemother 1997; 39:527-535
2. Cook DJ, Kollef MH: Risk factors for ICU-acquired pneumonia. JAMA 1998; 279:1605-1606
3. Vincent JL, Bihari DJ, Suter PM, et al: The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA 1995; 274:639-644
4. Warren DK, Shukla SJ, Olsen MA, et al: Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31:1312-1317
5. Fagon JY, Chastre J, Hance AJ, et al: Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest 1993; 103:547-553
6. Heyland DK, Cook DJ, Griffith L, et al: The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. Am J Respir Crit Care Med 1999; 159:1249-1256
7. Singh N, Rogers P, Atwood CW, et al: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-511
8. Safdar N, Dezfulian C, Collard HR, et al: Clinical and economic consequences of ventilator-associated pneumonia: A systematic review. Crit Care Med 2005; 33:2184-2193
9. Meduri GU, Mauldin GL, Wunderink RG, et al: Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. Chest 1994; 106:221-235
10. Garner JS, Jarvis WR, Emori TG, et al: CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-140
11. Kim JH, Gallis HA: Observations on spiraling empiricism: Its causes, allure, and perils, with particular reference to antibiotic therapy. Am J Med 1989; 87:201-206
12. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996; 153:1711-1725
13. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416
14. Rello J, Ausina V, Ricart M, et al: Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104:1230-1235
15. Trouillet JL, Chastre J, Vuagnat A, et al: Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157:531-539
16. Manhold C, von Rolbicki U, Brase R, et al: Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study. Intensive Care Med 1998; 24:1327-1330
17. Ost D, Hall CS, Joseph G, et al: Decision analysis of antibiotic and diagnostic strategies in ventilator-associated pneumonia. Am J Respir Crit Care Med 168:1060-1067
18. Klastersky J, Zinner SH: Synergistic combinations of antibiotics in Gram-negative bacillary infections. Rev Infect Dis 1982; 4:294-301
19. Hilf M, Yu VL, Sharp J, et al: Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540-546
20. Archibald L, Phillips L, Monnet D, et al: Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit. Clin Infect Dis 1997; 24:211-215
21. Koontz CS, Chang MC, Meredith JW: Effects of empiric antibiotic administration for suspected pneumonia on subsequent opportunistic pulmonary infections. Am Surg 2000; 66:1110-1114
22. Bliziotis IA, Samonis G, Vardakas KZ, et al: Effect of aminoglycoside and beta-lactam combination therapy vs. beta-lactam monotherapy on the emergence of antimicrobial resistance: A meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41:149-158
23. Fiel S: Guidelines and critical pathways for severe hospital-acquired pneumonia. Chest 2001; 119:412S-418S
24. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-187
25. Joshi M, Bernstein J, Solomkin J, et al: Piperacillin/tazobactam plus tobramycin vs. ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection: Piperacillin/tazobactam Nosocomial Pneumonia Study Group. J Antimicrob Chemother 1999; 43:389-397
26. Rodloff AC, Laubenthal HJ, Bastian A, et al: Comparative study of the cost-effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study. Anasthesiol Intensivmed Not-fallmed Schmerzther 1996; 31:172-180
27. Shah PM, Stille W: Cefotaxime vs. ceftriaxone for the treatment of nosocomial pneumonia: Results of a multicenter study. Diagn Microbiol Infect Dis 1995; 22:171-172
28. Bassetti D, Cruciani M, Solbiati M, et al: Comparative efficacy of ceftriaxone vs. ceftazidime in the treatment of nosocomial lower respiratory tract infections. Chemotherapy 1991; 37:371-375
29. Fernandez-Guerrero M, Gudiol F, Rodriguez-Torres A, et al: Nosocomial pneumonia: Comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations. Infection 1991; 19:S320-S325
30. Garber GE, Auger P, Chan RM, et al: A multicenter, open comparative study of parenteral cefotaxime and ceftriaxone in the treatment of nosocomial lower respiratory tract infections. Diagn Microbiol Infect Dis 1992; 15:85-88
31. Mangi RJ, Peccerillo KM, Ryan J, et al: Cefoperazone vs. ceftriaxone monotherapy of nosocomial pneumonia. Diagn Microbiol Infect Dis 1992; 15:441-447
32. Chuchalin AG, Novikov I, Avdeev SN, et al: Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract. Antibiot Khimioter 1997; 42:34-38
33. Marco V, Gobernado M, Santos M, et al: Comparative study of aztreonam in Gram-negative pneumonia vs. a therapeutic regimen that includes an aminoglycoside. Spanish Study Group. Chemotherapy 1989; 35:81-88
34. Stevens DL, Herr D, Lampiris H, et al: Linezolid vs. vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-1490
35. Wilcox M, Nathwani D, Dryden M: Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004; 53:335-344
36. Williams Hopkins D: Trovafloxacin vs. ciprofloxacin +/- clindamycin/metronidazole in patients with nosocomial pneumonia. Drugs 1999; 58:S323-S325
37. Bassaris HP, Williams Hopkins D, Daniel R: IV-to-oral switch therapy with trovafloxacin compared with IV ceftazidime/oral ciprofloxacin in the treatment of nosocomial pneumonia. Drugs 1999; 58:S309-S311
38. Mangi RJ, Ryan J, Berenson C, et al: Cefoperazone vs. ceftazidime monotherapy of nosocomial pneumonia. Am J Med 1988; 85:44-48
39. Mangi RJ, Greco T, Ryan J, et al: Cefoperazone vs. combination antibiotic therapy of hospital-acquired pneumonia. Am J Med 1988; 84:68-74
40. Trenholme GM, Schmitt BA, Spear J, et al: Randomized study of intravenous/oral ciprofloxacin vs. ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. Am J Med 1989; 87:116S-118S
41. Schmitt DV, Leitner E, Welte T, et al: Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia - A double blind prospective multicentre study. Infection 2006; 34:127-134
42. Baker A, Meridith JW, Chang M, et al: Bronchoscopically guided management of ventilator-associated pneumonia in trauma patients. J Bronchol 2003; 10:7-16
43. Damas P, Garweg C, Monchi M, et al: Combination therapy vs. monotherapy: A randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia Crit Care 2006; 10:R52
44. Rubinstein E, Cammarata S, Oliphant T, et al: Linezolid (PNU-100766) vs. vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-412
45. Muscedere J, Heyland DK, Dodek P, et al: A randomized trial of empiric broad-spectrum antibiotics and invasive diagnostic techniques for suspected ventilator-associated pneumonia. Abstr. Am J Respir Crit Care Med 2006; 3A525
46. Grudinina SA, Zubkov MM, Krotova LA, et al: Comparison of linezolid and vancomycin in nosocomial pneumonia: Results of the multicenter double-blind study. Antibiot Khimioter 2002; 47:12-17
47. Brun-Buisson C, Sollet JP, Schweich H, et al: Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin vs. ceftazidime/amikacin: A multicenter, randomized controlled trial. Clin Infect Dis 1998; 26:346-354
48. Alvarez LF: Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001; 13:70-81
49. Beaucaire G: Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. J Chemother 1995; 7:165S-173S
50. Beaucaire G, Nicolas H, Martin M, et al: Phare study. Comparative study of combined cefepime-amikacin vs. ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients. Multicenter group study. Ann Fr Anesth Reanim 1999; 18:186-195
51. Torres A, de Celis R, Rabinad E, et al: Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia: Comparative study against amikacin combined with cefotaxime. Chemotherapy 1989; 35:15S-24S
52. Polk HC Jr, Livingston DH, Fry DE, et al: Treatment of pneumonia in mechanically ventilated trauma patients: Results of a prospective trial. Arch Surg 1997; 132:1086-1092
53. Croce MA, Fabian TC, Stewart RM, et al: Empiric monotherapy vs. combination therapy of nosocomial pneumonia in trauma patients. J Trauma 1993; 35:303-309
54. Kljucar S, Heimesaat M, von Pritzbuer E, et al: Ceftazidime with and without tobramycin vs. azlocillin plus tobramycin in the therapy of bronchopulmonary infections in intensive care patients. Infection 1987; 15:S185-S191
55. Thomas PD, Daly S, Misan G, et al: Comparison of the efficacy and adverse effect profile of cefotaxime, 3g/day, and ceftriaxone, 2g/day, in the treatment of nosocomial lower respiratory tract infections in ICU patients. Eur Respir Rev 1994; 4:321-328
56. Saginur R, Garber G, Darling G, et al: Prospective, randomized comparison of intravenous and oral ciprofloxacin with intravenous ceftazidime in the treatment of nosocomial pneumonia. Can J Inf Dis 1997; 8:89-94
57. Wunderink RG, Rello J, Cammarata SK, et al: Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-1797
58. Beuscart C, Leroy O, Mouton Y, et al: Prospective randomized controlled study of a ceftazidime and pefloxacin combination vs. a ceftazidime and amikacin combination in the empirical treatment of pneumonia and nosocomial septicemia at intensive care units. Pathol Biol 1989; 37:496-499
59. Fink MP, Snydman DR, Niederman MS, et al: Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenemcilastatin. Antimicrob Agents Chemother 1994; 38:547-557
60. Schentag JJ, Vari AJ, Winslade NE, et al: Treatment with aztreonam or tobramycin in critical care patients with nosocomial Gram-negative pneumonia. Am J Med 1985; 78:34-41
61. Fagon J, Patrick H, Haas DW, et al: Treatment of Gram-positive nosocomial pneumonia: Prospective randomized comparison of quinupristin/dalfopristin vs. vancomycin. Am J Respir Crit Care Med 2000; 161:753-762
62. Norrby SR, Finch RG, Glauser M: Monotherapy in serious hospital-acquired infections: A clinical trial of ceftazidime vs. imipenem/cilastatin. J Antimicrob Chemother 1993; 31:927-937
63. Brown RB, Lemeshow S, Teres D, et al: Moxalactam vs carbenicillin plus tobramycin: Treatment of nosocomial gram-negative bacillary pneumonias in non-neutropenic patients. Curr Ther Res 1984; 36:557-564
64. Mouton YJ, Beuscart C: Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995; 36:S145-S156
65. Rapp RP, Billeter M, Hatton J, et al: Intravenous ciprofloxacin vs. ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. Clin Pharm 1991; 10:49-55
66. West M, Boulanger BR, Fogarty C, et al: Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25:485-506
67. Cepeda JA, Whitehouse T, Cooper B, et al: Linezolid vs. teicoplanin in the treatment of Gram-positive infections in the critically ill: A randomized, double-blind, multicentre study. J Antimicrob Chemother 2004; 53:345-355
68. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, et al: Efficacy and tolerability of piperacillin/tazobactam vs. ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: A prospective randomized multicenter trial. Intensive Care Med 2001; 27:493-502
69. Sieger B, Berman SJ, Geckler RW, et al: Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: A randomized study. Crit Care Med 1997; 25:1663-1670
70. Cometta A, Baumgartner JD, Lew D, et al: Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994; 38:1309-1313
71. Hartenauer U, Weilemann LS, Bodmann KF, et al: Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias. J Hosp Infect 1990; 15:S61-S64
72. Jaccard C, Troillet N, Harbarth S, et al: Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42:2966-2972
73. Reeves JH, Russell GM, Cade JF, et al: Comparison of ceftriaxone with cefotaxime in serious chest infections. Chest 1989; 96:1292-1297
74. Rubinstein E, Lode H, Grassi C: Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired Gram-negative infections. Clin Infect Dis 1995; 20:1217-1228
75. Torres A, Bauer TT, Leon-Gil C, et al: Treatment of severe nosocomial pneumonia: A prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000; 55:1033-1039
76. Zanetti G, Bally F, Greub G, et al: Cefepime vs. imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: A multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47:3442-3447
77. Wolff M: Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients. The Cefpirome Pneumonia Study Group. Antimicrob Agents Chemother 1998; 42:28-36
78. Colardyn F, Faulkner KL: Intravenous meropenem vs. imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother 1996; 38:523-537
79. Garau J, Blanquer J, Cobo L, et al: Prospective, randomised, multicentre study of meropenem vs. imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997; 16:789-796
80. Mouton Y, Deboscker Y, Bazin C, et al: Prospective, randomized, controlled study of imipenem-cilastatin vs. cefotaxime-amikacin in the treatment of lower respiratory tract infection and septicemia at intensive care units. Presse Med 1990; 19:607-612
81. Rapp RP, Young B, Foster TS, et al: Ceftazidime vs. tobramycin/ ticarcillin in treating hospital acquired pneumonia and bacteremia. Pharmacotherapy 1984; 4:211-215
82. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al: Beta lactam monotherapy vs. beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668
83. Fagon JY, Chastre J, Wolff M, et al: Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: A randomized trial. Ann Intern Med 2000; 132:621-630
84. Heyland DK, Cook DJ, Marshall J, et al: The clinical utility of invasive diagnostic techniques in the setting of ventilator-associated pneumonia. Canadian Critical Care Trials Group. Chest 1999; 115:1076-1084
85. Lareau SC, Ryan KJ, Diener CF: The relationship between frequency of ventilator circuit changes and infectious hazard. Am Rev Respir Dis 1978; 118:493-496
86. Celis R, Torres A, Gatell JM, et al: Nosocomial pneumonia: A multivariate analysis of risk and prognosis. Chest 1988; 93:318-324
87. Fowler RA, Flavin KE, Barr J, et al: Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest 2003; 123:835-844
88. Kollef MH, Sherman G, Ward S, et al: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474
89. Lasagna L: Placebos and controlled trials under attack. Eur J Clin Pharmacol 1979; 15:373-374
90. Temple R, Ellenberg SS: Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med 2000; 133:455-463
91. Giamarellou H, Mandragos K, Bechrakis P, et al: Pefloxacin vs. imipenem in the therapy of nosocomial lung infections of intensive care unit patients. J Antimicrob Chemother 1990; 26:S117-S127
92. Kollef MH, Rello J, Cammarata SK, et al: Clinical cure and survival in Gram-positive ventilator-associated pneumonia: Retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30:388-394